Home
MYGN
MYGN News

Latest Myriad Genetics Inc. (MYGN) News on December 18, 2024

Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?

Zacks

a day ago

Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?

MT Newswires

7 days ago

Myriad Genetics Expects to Reach Resolution With UnitedHealthcare Over Pharmacogenetic Testing Before Yearend

Argus Research

8 days ago

MYGN: Lowering target price to $12.00

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

GlobeNewswire

8 days ago

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

GlobeNewswire

8 days ago

Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

GlobeNewswire

8 days ago

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?

Zacks

8 days ago

New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

GlobeNewswire

9 days ago

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

MT Newswires

9 days ago

Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment

GlobeNewswire

9 days ago

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment

Argus Research

15 days ago

MYGN: What does Argus have to say about MYGN?

MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2

Zacks

23 days ago

MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

GlobeNewswire

a month ago

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

GlobeNewswire

a month ago

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley

TipRanks

a month ago

Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley

MT Newswires

a month ago

Morgan Stanley Cuts Price Target on Myriad Genetics to $21 From $32, Keeps Equalweight Rating

MYGN Stock Might Gain From SneakPeek Availability in Retail Stores

Zacks

a month ago

MYGN Stock Might Gain From SneakPeek Availability in Retail Stores

MT Newswires

a month ago

Myriad Genetics Says Fetal Gender Test Available at Over 8,000 Stores in US

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch

GlobeNewswire

a month ago

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch

Argus Research

a month ago

MYGN: Lowering target price to $13.00

Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

a month ago

Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View

Zacks

a month ago

MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View

Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ...

GuruFocus.com

a month ago

Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ...

Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics

Zacks

a month ago

Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics

Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates

Zacks

a month ago

Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates

Associated Press Finance

a month ago

Myriad: Q3 Earnings Snapshot

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

GlobeNewswire

a month ago

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

BIIB vs. MYGN: Which Stock Is the Better Value Option?

Zacks

a month ago

BIIB vs. MYGN: Which Stock Is the Better Value Option?

Argus Research

a month ago

MYGN: Lowering target price to $14.00

MT Newswires

a month ago

Myriad Genetics Disputes Inclusion of GeneSight in UnitedHealthcare's Coverage Restriction

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

GlobeNewswire

a month ago

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

Myriad weakness due to UnitedHealth coverage update, says Stephens

TipRanks

2 months ago

Myriad weakness due to UnitedHealth coverage update, says Stephens

Morningstar Research

2 months ago

Analyst Report: Myriad Genetics, Inc.

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

GlobeNewswire

2 months ago

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?

Zacks

2 months ago

Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?

Morningstar Research

2 months ago

Analyst Report: Myriad Genetics, Inc.

Myriad Genetics Shares Fall Despite Partnership With jscreen

Zacks

2 months ago

Myriad Genetics Shares Fall Despite Partnership With jscreen

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access

GlobeNewswire

2 months ago

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration

GlobeNewswire

2 months ago

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week

Simply Wall St.

2 months ago

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests

Zacks

2 months ago

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests

Myriad signs five partnerships to study MRD testing in breast cancer

Clinical Trials Arena

2 months ago

Myriad signs five partnerships to study MRD testing in breast cancer

Argus Research

2 months ago

MYGN: What does Argus have to say about MYGN?

MT Newswires

2 months ago

Myriad Genetics Outlines Five Projects on Studying Breast Cancer Test

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

GlobeNewswire

2 months ago

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

Myriad and Ultima to study UG 100 sequencing platform for genomics clinical tests

Medical Device Network

2 months ago

Myriad and Ultima to study UG 100 sequencing platform for genomics clinical tests

MT Newswires

3 months ago

Myriad Genetics, Ultima Genomics Collaborate to Explore UG 100 Sequencing Platform

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

GlobeNewswire

3 months ago

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

MT Newswires

3 months ago

Myriad Genetics Gets Third Patent for Molecular Residual Disease Assay

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

GlobeNewswire

3 months ago

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

BMRN or MYGN: Which Is the Better Value Stock Right Now?

Zacks

3 months ago

BMRN or MYGN: Which Is the Better Value Stock Right Now?

Morningstar Research

3 months ago

Analyst Report: Myriad Genetics, Inc.

MT Newswires

3 months ago

Myriad Genetics Has Many Opportunities for Growth, Needs Sustained Execution, Morgan Stanley Says

MT Newswires

3 months ago

Update: Morgan Stanley Initiates Myriad Genetics at Equalweight With $32 Price Target

MT Newswires

3 months ago

Morgan Stanley Initiates Myriad Genetics at Equalweight

Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock

Zacks

3 months ago

Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock

Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

GlobeNewswire

3 months ago

Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Should You Continue to Retain MYGN Stock in Your Portfolio?

Zacks

3 months ago

Should You Continue to Retain MYGN Stock in Your Portfolio?

Morningstar Research

3 months ago

Analyst Report: Myriad Genetics, Inc.

Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN)

GuruFocus.com

3 months ago

Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN)

Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN)

GuruFocus.com

3 months ago

Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN)

MT Newswires

3 months ago

Myriad Genetics Insider Sold Shares Worth $400,800, According to a Recent SEC Filing

Insider Sale: Director Heinrich Dreismann Sells Shares of Myriad Genetics Inc (MYGN)

GuruFocus.com

3 months ago

Insider Sale: Director Heinrich Dreismann Sells Shares of Myriad Genetics Inc (MYGN)

MT Newswires

3 months ago

Myriad Genetics Insider Sold Shares Worth $270,520, According to a Recent SEC Filing

Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?

Zacks

3 months ago

Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?

Myriad Genetics to Host Investor Event on October 9, 2024

GlobeNewswire

3 months ago

Myriad Genetics to Host Investor Event on October 9, 2024

MT Newswires

3 months ago

Myriad Genetics Insider Sold Shares Worth $1,285,851, According to a Recent SEC Filing

Insider Sale: Director Colleen Reitan Sells Shares of Myriad Genetics Inc (MYGN)

GuruFocus.com

3 months ago

Insider Sale: Director Colleen Reitan Sells Shares of Myriad Genetics Inc (MYGN)

Morningstar Research

3 months ago

Analyst Report: Myriad Genetics, Inc.

MT Newswires

3 months ago

Myriad Genetics Discontinues Analysis on GeneSight Testing Due to Control Group Disparities

New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues

Zacks

3 months ago

New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues

Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term

Zacks

4 months ago

Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term

MT Newswires

4 months ago

Wells Fargo Initiates Myriad Genetics at Overweight With $35 Price Target

Argus Research

4 months ago

MYGN: Lowering target price to $23.00

Insider Sale at Myriad Genetics Inc (MYGN): SVP, Chief of Staff Margaret Ancona Sells Shares

GuruFocus.com

4 months ago

Insider Sale at Myriad Genetics Inc (MYGN): SVP, Chief of Staff Margaret Ancona Sells Shares

Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

GlobeNewswire

4 months ago

Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Argus Research

4 months ago

MYGN: What does Argus have to say about MYGN?

Insider Sale: Director Rashmi Kumar Sells 7,500 Shares of Myriad Genetics Inc (MYGN)

GuruFocus.com

4 months ago

Insider Sale: Director Rashmi Kumar Sells 7,500 Shares of Myriad Genetics Inc (MYGN)

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

4 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Morningstar Research

4 months ago

Analyst Report: Myriad Genetics, Inc.

Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised

Zacks

4 months ago

Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised

Myriad Genetics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

4 months ago

Myriad Genetics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Morningstar Research

4 months ago

Analyst Report: Myriad Genetics, Inc.

MT Newswires

4 months ago

Myriad Genetics Swings to Q2 Adjusted Profit, Sales Jump; Lifts 2024 Guidance

Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

4 months ago

Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates

Zacks

4 months ago

Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates

Associated Press Finance

4 months ago

Myriad: Q2 Earnings Snapshot

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

GlobeNewswire

4 months ago

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific

GlobeNewswire

5 months ago

Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer

GlobeNewswire

5 months ago

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer

Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024

GlobeNewswire

5 months ago

Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024

Argus Research

5 months ago

MYGN: What does Argus have to say about MYGN?

INCY or MYGN: Which Is the Better Value Stock Right Now?

Zacks

5 months ago

INCY or MYGN: Which Is the Better Value Stock Right Now?

What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk

GlobeNewswire

5 months ago

What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk

Argus Research

5 months ago

MYGN: Raising target price to $22.00

Myriad Genetics (MYGN) Expands in MRD Testing With New Collab

Zacks

5 months ago

Myriad Genetics (MYGN) Expands in MRD Testing With New Collab

MT Newswires

5 months ago

Myriad Genetics, Personalis to Cross-License IP on Minimal Residual Disease Tests

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

GlobeNewswire

5 months ago

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

Myriad Genetics (MYGN) Advances in MRD Space With New Patent

Zacks

5 months ago

Myriad Genetics (MYGN) Advances in MRD Space With New Patent

Argus Research

5 months ago

MYGN: What does Argus have to say about MYGN?

Share on Social Networks: